Granata Bio is a U.S. based biopharmaceutical company committed to advancing innovation in women's health and infertility. Founded in 2018, the company's pipeline includes a range of fertility therapies, with collaborations spanning multiple drug classes to address unmet needs in reproductive medicine. Granata Bio is the parent company of Oviva Therapeutics, Inc., a wholly owned subsidiary developing first-in-class therapeutics aimed at preserving ovarian function and extending female health span.